Tin tức & Cập nhật
Lọc theo Chuyên ngành:
SGLT-2I–MRA combo yields maximal kidney, cardiovascular protection in T2DM, CKD
Sodium-glucose cotransporter-2 inhibitors (SGLT-2Is) confer the greatest reduction in kidney and cardiovascular risks in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), according to a study.
SGLT-2I–MRA combo yields maximal kidney, cardiovascular protection in T2DM, CKD
05 Mar 2023
Neoadjuvant immunotherapy delivers in cisplatin-ineligible bladder cancer
The use of pembrolizumab in the neoadjuvant setting appears to be associated with a higher rate of downstaging and a survival advantage among patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based neoadjuvant chemotherapy, according to a study presented at this year’s ASCO Genitourinary Cancers Symposium.
Neoadjuvant immunotherapy delivers in cisplatin-ineligible bladder cancer
03 Mar 2023
Nivolumab plus cabozantinib superior to sunitinib in renal cell carcinoma
First-line treatment of advanced renal cell carcinoma (aRCC) with nivolumab plus cabozantinib (N+C) results in sustained survival and response benefits at 3 years minimum follow-up, which is consistent with previous follow-ups, according to a study presented at the 2023 ASCO GU Cancers Symposium.
Nivolumab plus cabozantinib superior to sunitinib in renal cell carcinoma
03 Mar 2023
Mirabegron, vibegron equally effective in postmenopausal women with OAB
Mirabegron appears to be as good as vibegron in the treatment of overactive bladder (OAB) in postmenopausal women, with both drugs helping improve symptoms and the parameters of voiding diary, according to a study.
Mirabegron, vibegron equally effective in postmenopausal women with OAB
03 Mar 2023
Final PROpel data confirm OS advantage with abiraterone plus olaparib
The combination of olaparib plus abiraterone in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) appears to show a consistent trend toward overall survival (OS) benefit, according to the results of the final prespecified analysis of the phase III PROpel study presented at ASCO GU 2023.
Final PROpel data confirm OS advantage with abiraterone plus olaparib
01 Mar 2023
Use of biomarkers, biologics ups success rate of clinical trials in gastric cancer
Success rates of clinical trials in gastric cancer tend to improve with the use of implementing biomarkers, receptor-targeted therapies, and biologics in clinical development, suggests a recent study.
Use of biomarkers, biologics ups success rate of clinical trials in gastric cancer
01 Mar 2023
Statin therapy reduces major vascular events after stroke
Treatment with statin results in a decrease in major vascular events following acute ischaemic stroke, even in patients with low or well-controlled low-density lipoprotein cholesterol (LDL-C), as shown in a study presented at ISC 2023.
Statin therapy reduces major vascular events after stroke
01 Mar 2023
DOACs, VKAs show similar efficacy, safety for VTE in octogenarians
In an international multi-database cohort study, direct oral anticoagulants (DOACs) demonstrated comparable efficacy and safety with vitamin K antagonists (VKAs) for octogenarians with venous thromboembolism (VTE).